<?xml version="1.0" encoding="UTF-8"?>
<p id="Par18">The trial (
 <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link> number, NCT02822326) was designed to assess the safety and feasibility of infusing 1928zT2 T cells in patients with relapsed or refractory B-ALL and was approved by the Ethics Committee of Guangdong General Hospital. Here, we reported the first three enrolled ALL patients with extramedullary involvement (TableÂ 
 <xref rid="Tab1" ref-type="table">1</xref>).
</p>
